| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 3,042 | 3,812 | 3,410 | 3,137 | 3,312 | 3,581 | 3,699 | 3,717 | 3,510 | 3,584 | 4,102 | 3,887 | 3,536 | 4,016 | 4,081 | 3,985 | 4,366 | 3,973 | 4,365 | 4,307 | 4,395 | 4,342 | 5,026 | 5,241 | 4,645 | 5,536 | 5,547 | 5,534 | 5,288 | 5,421 | 5,882 | 5,845 | 5,801 | 6,406 | 6,766 | 6,690 | 6,332 | 6,785 | 7,152 | 7,183 | 6,887 |
| Expenses | 2,585 | 2,784 | 2,669 | 2,688 | 3,138 | 3,039 | 3,070 | 2,970 | 3,076 | 2,879 | 3,278 | 3,095 | 3,219 | 3,213 | 3,310 | 3,300 | 3,443 | 3,084 | 3,486 | 3,613 | 3,743 | 3,297 | 3,862 | 3,938 | 3,810 | 4,283 | 4,294 | 4,248 | 4,568 | 4,232 | 4,526 | 4,403 | 4,748 | 4,835 | 4,944 | 5,051 | 4,847 | 4,978 | 5,165 | 5,084 | 5,192 |
| EBITDA | 457 | 1,028 | 741 | 450 | 174 | 543 | 629 | 748 | 434 | 705 | 824 | 792 | 317 | 803 | 771 | 685 | 923 | 889 | 879 | 694 | 652 | 1,045 | 1,164 | 1,303 | 835 | 1,253 | 1,253 | 1,286 | 720 | 1,190 | 1,356 | 1,442 | 1,053 | 1,571 | 1,821 | 1,639 | 1,484 | 1,807 | 1,986 | 2,099 | 1,695 |
| Operating Profit % | 13 % | 26 % | 21 % | 12 % | 4 % | 15 % | 16 % | 17 % | 12 % | 16 % | 18 % | 19 % | 8 % | 16 % | 16 % | 16 % | 19 % | 21 % | 18 % | 15 % | 13 % | 23 % | 22 % | 24 % | 17 % | 22 % | 22 % | 22 % | 13 % | 20 % | 21 % | 23 % | 16 % | 23 % | 25 % | 22 % | 20 % | 25 % | 26 % | 27 % | 21 % |
| Depreciation | 136 | 149 | 158 | 177 | 270 | 204 | 229 | 258 | 632 | 213 | 302 | 522 | 285 | 241 | 282 | 293 | 510 | 268 | 283 | 278 | 346 | 269 | 265 | 248 | 285 | 261 | 253 | 248 | 290 | 254 | 299 | 272 | 346 | 239 | 290 | 233 | 288 | 247 | 272 | 280 | 309 |
| Interest | 43 | 64 | 64 | 31 | 48 | 32 | 35 | 59 | 33 | 28 | 42 | 9 | 35 | 35 | 44 | 44 | 45 | 52 | 46 | 46 | 53 | 46 | 39 | 48 | 28 | 30 | 38 | 21 | 18 | 18 | 26 | 32 | 34 | 16 | 26 | 30 | 18 | 18 | 15 | 15 | 14 |
| Profit Before Tax | 390 | 892 | 595 | 322 | -82 | 401 | 444 | 514 | -137 | 557 | 574 | 340 | 199 | 620 | 509 | 449 | 501 | 663 | 681 | 506 | 328 | 799 | 926 | 1,022 | 544 | 996 | 996 | 1,054 | 448 | 975 | 1,100 | 1,218 | 745 | 1,375 | 1,594 | 1,474 | 1,259 | 1,611 | 1,789 | 1,916 | 1,504 |
| Tax | 106 | 242 | 43 | 54 | 5 | 57 | 74 | 129 | -74 | 132 | 139 | -63 | 46 | 175 | 142 | 127 | 144 | 216 | 207 | 167 | 89 | 233 | 266 | 270 | 132 | 286 | 287 | 297 | 77 | 268 | 303 | 410 | 224 | 377 | 439 | 405 | 327 | 436 | 484 | 342 | 290 |
| Net Profit | 284 | 650 | 552 | 269 | -87 | 344 | 370 | 385 | -63 | 425 | 435 | 404 | 153 | 446 | 367 | 322 | 358 | 447 | 475 | 339 | 239 | 566 | 659 | 752 | 412 | 710 | 709 | 757 | 371 | 706 | 797 | 808 | 522 | 998 | 1,155 | 1,068 | 932 | 1,176 | 1,305 | 1,575 | 1,214 |
| EPS in ₹ | 3.24 | 8.09 | 6.76 | 3.24 | -1.16 | 4.22 | 4.41 | 4.66 | -0.77 | 5.08 | 5.25 | 4.98 | 2.22 | 5.60 | 4.68 | 4.12 | 4.56 | 5.93 | 5.85 | 4.35 | 3.05 | 7.17 | 8.25 | 9.28 | 5.13 | 8.86 | 8.82 | 9.03 | 4.49 | 8.51 | 9.78 | 9.92 | 6.51 | 12.34 | 14.01 | 13.08 | 11.63 | 14.58 | 16.13 | 19.45 | 15.13 |
Cipla
Cipla
1,487.90
+14.40
(0.98%)
There are new updates from the company1 day ago
View
Market Cap
1,20,178.85 Cr
EPS
65.29
PE Ratio
23.13
Dividend Yield
1.09 %
Industry
Healthcare52 Week High
1,702.05
52 Week Low
1,335.00
PB Ratio
3.82
Debt to Equity
0.02
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from35 analysts
Company News
View All News
Cipla is set to announce its June quarter earnings on July 25. Analysts expect mixed performance with revenue growth projected between 3.6-9% YoY, driven by healthy India sales but offset by declining US generics business. Net profit estimates range from Rs 1,140 crore to Rs 1,380 crore, reflecting a YoY change of -3% to +17.2%. US revenue is expected to decline 12-13% YoY due to lower gRevlimid prices, while domestic formulations segment is projected to grow 8-9% YoY. EBITDA margins are likely to contract by about 100 basis points YoY due to reduced contribution from high-margin US sales. Key focus areas include US business trajectory, pricing trends in key products, and recovery in India's trade generics segment.
Cipla has invested ₹5 crore to acquire a 20% stake in Icaltech Innovations. The investment is aimed at strengthening Cipla's respiratory healthcare segment.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,692.00 | #1 4,05,967.48 | 35.24 | #1 54,729.00 | 12.06 | #1 10,980 | -18.99 | 52.71 | |
6,618.50 | 1,75,700.38 | 80.64 | 9,712.00 | 0.89 | 2,191 | 23.05 | 42.75 | |
1,487.90 | #3 1,20,178.85 | #4 23.13 | #4 28,409.50 | #9 7.12 | #3 5,291 | #2 30.28 | 49.20 | |
3,519.90 | 1,19,129.41 | 62.79 | 11,539.40 | 11.59 | 1,911 | 10.91 | 65.81 | |
2,589.50 | 1,06,876.11 | 61.82 | 12,744.20 | 19.57 | 2,007 | -10.91 | 58.90 | |
1,265.50 | 1,05,614.97 | #1 18.77 | 33,741.20 | 16.73 | 5,725 | 1.26 | 47.24 | |
971.25 | 97,730.48 | 20.83 | 23,511.00 | 13.82 | 4,615 | -0.19 | 50.79 | |
1,941.40 | 88,662.86 | 27.01 | 22,909.50 | #1 19.94 | 3,306 | #1 112.49 | 49.98 | |
34,580.00 | 73,480.09 | 52.18 | 6,684.70 | 10.80 | 1,414 | 27.83 | 60.84 | |
1,114.10 | 64,707.11 | 18.78 | 31,378.10 | 17.55 | 3,366 | -0.50 | 43.00 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
7.12 %
Net Income Growth
27.33 %
Cash Flow Change
21.07 %
ROE
9.10 %
ROCE
2.32 %
EBITDA Margin (Avg.)
5.95 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 15,718 | 21,128 | 21,037 | 22,861 | 23,963 | 23,663 | 25,152 | 27,101 | 29,463 | 32,718 | 37,387 |
| Fixed Assets | 6,830 | 9,369 | 9,492 | 9,950 | 9,608 | 9,683 | 9,516 | 9,683 | 9,161 | 9,607 | 10,006 |
| Current Assets | 7,591 | 8,841 | 8,736 | 10,814 | 12,427 | 11,706 | 13,210 | 14,711 | 16,805 | 19,392 | 23,249 |
| Capital Work in Progress | 581 | 2,061 | 1,683 | 981 | 676 | 825 | 969 | 766 | 1,093 | 1,153 | 1,566 |
| Investments | 390 | 758 | 973 | 1,259 | 2,554 | 1,471 | 2,710 | 2,551 | 3,662 | 5,449 | 7,933 |
| Other Assets | 7,917 | 8,940 | 8,889 | 10,670 | 11,125 | 11,684 | 11,957 | 14,101 | 15,547 | 16,509 | 17,882 |
| Total Liabilities | 15,718 | 21,128 | 21,037 | 22,861 | 23,963 | 23,663 | 25,152 | 27,101 | 29,463 | 32,718 | 37,387 |
| Current Liabilities | 3,881 | 7,776 | 3,374 | 3,832 | 3,772 | 4,393 | 4,591 | 4,913 | 5,110 | 5,246 | 5,484 |
| Non Current Liabilities | 854 | 1,486 | 4,682 | 4,447 | 4,848 | 3,212 | 1,975 | 1,071 | 640 | 670 | 614 |
| Total Equity | 10,982 | 11,866 | 12,982 | 14,582 | 15,344 | 16,057 | 18,586 | 21,117 | 23,714 | 26,802 | 31,289 |
| Reserve & Surplus | 10,629 | 11,356 | 12,383 | 14,068 | 14,851 | 15,602 | 18,165 | 20,680 | 23,246 | 26,545 | 31,032 |
| Share Capital | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 162 | 162 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 389 | 312 | -248 | 243 | -345 | 234 | 141 | -132 | -97 | -49 | 30 |
| Investing Activities | -950 | -4,533 | -1,304 | -834 | -1,688 | 114 | -2,374 | -1,858 | -2,376 | -2,983 | -3,682 |
| Operating Activities | 1,173 | 1,741 | 2,382 | 1,463 | 1,691 | 3,068 | 3,755 | 3,326 | 3,238 | 4,134 | 5,005 |
| Financing Activities | 165 | 3,104 | -1,326 | -386 | -349 | -2,949 | -1,240 | -1,600 | -958 | -1,200 | -1,293 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 36.73 % | 36.72 % | 36.12 % | 36.11 % | 33.63 % | 33.61 % | 33.61 % | 33.61 % | 33.55 % | 33.47 % | 33.47 % | 33.47 % | 33.47 % | 30.91 % | 30.92 % | 29.19 % | 29.20 % | 29.19 % |
| FIIs | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 25.74 % | 25.73 % | 25.83 % | 27.81 % | 28.80 % | 26.65 % | 26.28 % | 25.24 % |
| DIIs | 16.79 % | 15.91 % | 17.41 % | 17.61 % | 17.72 % | 17.12 % | 19.71 % | 21.13 % | 22.10 % | 24.34 % | 24.18 % | 24.33 % | 24.42 % | 24.95 % | 24.16 % | 27.71 % | 28.15 % | 29.26 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.24 % | 16.14 % | 16.01 % | 15.97 % | 15.55 % | 15.41 % | 14.83 % | 14.72 % | 14.85 % | 14.66 % | 14.45 % | 14.34 % | 14.20 % | 14.24 % | 14.16 % | 14.29 % | 14.13 % | 14.10 % |
| Others | 30.23 % | 31.22 % | 30.47 % | 30.30 % | 33.10 % | 33.86 % | 31.84 % | 30.53 % | 29.50 % | 27.53 % | 2.16 % | 2.12 % | 2.08 % | 2.09 % | 1.95 % | 2.15 % | 2.23 % | 2.20 % |
| No of Share Holders | 3,64,796 | 4,08,401 | 4,10,831 | 4,51,365 | 4,18,584 | 4,18,910 | 3,88,864 | 4,04,182 | 4,75,293 | 4,66,513 | 4,26,861 | 4,25,731 | 4,36,154 | 4,63,569 | 4,70,234 | 5,25,114 | 5,43,420 | 5,49,655 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 2 | 3 | 3 | 4 | 5 | 5 | 8.5 | 13 | 16 |
| Dividend Yield (%) | 0.00 | 0.37 | 0.57 | 0.71 | 0.49 | 0.49 | 0.56 | 0.57 | 0.9 | 1.09 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 25 Jul 2025 |  Quarterly Result Announcement | NA | 25 Jul 2025 | 1,505.90 | 1,487.90 |
| 16 Jul 2025 |  Annual General Meeting | NA | 16 Jul 2025 | 1,512.00 | 1,490.90 |
| 27 Jun 2025 |  Dividend | ₹ 3.00 /share | 27 Jun 2025 | 1,512.00 | 1,513.80 |
| 27 Jun 2025 | Dividend | ₹ 13.00 /share | 27 Jun 2025 | 1,512.00 | 1,513.80 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 1,415.55 | 1,512.00 |
| 28 Jan 2025 | Quarterly Result Announcement | NA | 28 Jan 2025 | 1,510.25 | 1,396.10 |
| 29 Oct 2024 | Quarterly Result Announcement | NA | 29 Oct 2024 | 1,654.10 | 1,503.50 |
| 20 Aug 2024 | Annual General Meeting | NA | 20 Aug 2024 | 1,358.80 | 1,575.50 |
| 02 Aug 2024 | Dividend | ₹ 13.00 /share | 02 Aug 2024 | 1,358.80 | 1,546.15 |
| 21 Jul 2023 | Dividend | ₹ 8.50 /share | 21 Jul 2023 | 943.95 | 1,056.20 |
| 26 Aug 2022 | Annual General Meeting | NA | 26 Aug 2022 | 955.10 | 1,025.45 |
| 10 Aug 2022 | Dividend | ₹ 5.00 /share | 08 Aug 2022 | 937.55 | 1,029.55 |
| 11 Aug 2021 | Dividend | ₹ 5.00 /share | 09 Aug 2021 | 898.60 | 912.60 |
Announcements
Transcript Of The 89Th Annual General Meeting
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Acquisition3 days ago
3 days agoDisclosures under Reg. 29(1) of SEBI (SAST) Regulations 20116 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Change in Management8 days ago
8 days agoShareholder Meeting / Postal Ballot-Outcome of AGM8 days ago
8 days agoShareholder Meeting / Postal Ballot-Scrutinizers Report8 days ago
8 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 201810 days ago
10 days agoIntimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 12, 2025
Jul 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 10, 2025
Jul 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 02, 2025
Jul 02, 2025Board Meeting Intimation for Quarter Ended 30Th June 2025 Under SEBI Listing RegulationsJul 01, 2025
Jul 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 27, 2025
Jun 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 20, 2025
Jun 20, 2025Business Responsibility and Sustainability Reporting (BRSR)Jun 19, 2025
Jun 19, 2025Notice Of 89Th Annual General Meeting And Integrated Annual Report For FY 2024-25Jun 19, 2025
Jun 19, 2025Reg. 34 (1) Annual Report.Jun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 12, 2025
Jun 12, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 07, 2025
Jun 07, 2025Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 06, 2025
Jun 06, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 01, 2025
Jun 01, 2025USFDA Inspection At CompanyS Manufacturing Facility In Bommasandra Bengaluru IndiaMay 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-AcquisitionMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 26, 2025
May 26, 2025Clarification - Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Submitted On 13Th May 2025May 23, 2025
May 23, 2025Announcement under Regulation 30 (LODR)-AcquisitionMay 19, 2025
May 19, 2025Update On USFDA Inspection At Facility Of Sitec Labs Limited In Mahape Navi Mumbai IndiaMay 17, 2025
May 17, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 16, 2025
May 16, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2025
May 13, 2025Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 13, 2025
May 13, 2025Board Meeting Outcome for Outcome Of Board MeetingMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 13, 2025
May 13, 2025Appointment Of Cost Auditor Secretarial Auditor And Statutory AuditorsMay 13, 2025
May 13, 2025Record Date For Payment Of Final Dividend For FY 2024-25May 13, 2025
May 13, 2025Corporate Action-Board approves DividendMay 13, 2025
May 13, 2025Financial Results And Declaration Of DividendMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 30, 2025
Apr 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 30, 2025
Apr 30, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 29, 2025
Apr 29, 2025Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 24, 2025
Apr 24, 2025Update On USFDA Inspection At Manufacturing Facility Of Medispray In Kundaim Goa IndiaApr 17, 2025
Apr 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 17, 2025
Apr 17, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 17, 2025
Apr 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 16, 2025
Apr 16, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 11, 2025
Apr 11, 2025Technical Indicators
RSI(14)
Neutral 49.20
ATR(14)
Less Volatile 21.02
STOCH(9,6)
Neutral 41.47
STOCH RSI(14)
Neutral 32.47
MACD(12,26)
Bearish -1.76
ADX(14)
Weak Trend 21.65
UO(9)
Bearish 62.44
ROC(12)
Downtrend But Slowing Down -1.50
WillR(14)
Neutral -49.77
Mutual Fund Holdings
Kotak Arbitrage Fund Direct-Growth 
HDFC Manufacturing Fund Direct - Growth 
Canara Robeco Equity Hybrid Fund Direct-Growth 
Parag Parikh Flexi Cap Fund Direct-Growth 
Tata Balanced Advantage Fund Direct - Growth 
ICICI Prudential Equity Arbitrage Direct-Growth 
Axis India Manufacturing Fund Direct-Growth 
Edelweiss Aggressive Hybrid Fund Direct - Growth 
Invesco India Arbitrage Fund Direct-Growth 
Baroda BNP Paribas Health and Wellness Fund Direct-Growth 
Sundaram Dividend Yield Fund Direct-Growth 
Bandhan Multi Asset Allocation Fund Direct-Growth 
DSP Equity Savings Fund Direct-Growth 
SBI Arbitrage Opportunities Fund Direct-Growth About Cipla
Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS therapeutic areas. Cipla has a global presence with manufacturing facilities and operations in India and international markets, including the United States, South Africa, and other countries. The company focuses on developing and producing generic and branded generic medicines, as well as expanding into consumer healthcare, biosimilars, and specialty business through its New ventures segment.
Website
Chairperson NameY K Hamied
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
